Floatz logo

Lofexidine

Opioid Withdrawal (Disorder)

USWM, LLC (dba US WorldMeds)Small moleculePhase 2Dormant
CCC
53/ 100
Provisional rating · Methodology v0.2

Rating breakdown

Clinical Evidence
38/ 100
Competitive Position
95/ 100

Competitive context

2 Active assets in the Opioid Withdrawal (Disorder) cohort.

Asset / SponsorPhaseRating
Probenecid
University of Calgary
Phase 2CCC
Buprenorphine
Medical University of South Carolina
Phase 1/2CCC
Buspirone
Johns Hopkins University
Phase 1CC
Phentermine
Center for Weight Management, California
N/AD
CBOT
Evon Medics LLC
Phase 2NR

Need depth?

Order a full diligence report on this asset.

Order report →

Are you the sponsor?

Submit your data room for a Verified Rating. The public-data rating remains visible alongside.

Contact →